← Leaderboards
Chad V Pecot
Univ Of North Carolina Chapel Hill
$5,843,920
Attributed
$8,339,726
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,339,726 · 6
By mechanism
R01$5,954,781 · 3
R44$2,113,685 · 1
R41$224,995 · 1
P30$46,265 · 1
Top collaborators
- Andrew Carl Dudley5 shared
- Lyla Stanland3 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Jonathan C. Schisler$4,384,377
- Daniel Walker Belsky$6,855,166
- Charles M Perou$46,508,459
- Stephen Vernon Frye$8,267,632
- Deborah F. Tate$23,255,914
Others in their field
Other Emerging Leaders on “Cessation Of Life”
- Xinhua Li · Nano Terra, Inc.$32,520,955
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Abraham Aizer Brody · New York University School Of Medicine$21,799,826
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$20,810,724
- Jeffrey Reich · Sparian Biosciences, Inc.$20,633,040
- Beth Baseler · Leidos Biomedical Research, Inc.$18,109,529
Research focus
Cessation Of LifeTumorLung AdenocarcinomaCancer EtiologyProgramsTargeted TreatmentSignal TransductionLungIn VivoNeoplasm MetastasisSquamous Cell Lung CarcinomaMalignant NeoplasmsMediatingMalignant Neoplasm Of LungPathway InteractionsProteinsMouse ModelImmuneCancer TypeAngiogenesisInflammatoryImmune Checkpoint BlockadeLeadLigands
Grant awards (18)
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics$919,020
R44 · FY2025 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$580,098
R01 · FY2025 · CA · contact PI
Circle RNA Regulation of Lung Cancer Metastasis$398,845
R01 · FY2025 · CA · contact PI
Molecular Therapeutics Research Program$46,265
P30 · FY2025 · CA · contact PI
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics$919,020
R44 · FY2024 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$551,095
R01 · FY2024 · CA · contact PI
Circle RNA Regulation of Lung Cancer Metastasis$360,511
R01 · FY2024 · CA · contact PI
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$568,496
R01 · FY2023 · CA · contact PI
Circle RNA Regulation of Lung Cancer Metastasis$328,960
R01 · FY2023 · CA · contact PI
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics$275,645
R44 · FY2023 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$568,496
R01 · FY2022 · CA · contact PI
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices$609,743
R01 · FY2021 · CA · contact PI
Immune Regulation of Lung Squamous Metastasis$387,674
R01 · FY2021 · CA · contact PI
Immune Regulation of Lung Squamous Metastasis$392,837
R01 · FY2020 · CA · contact PI
Development of EFTX-001 to target KRAS mutations in cancer$224,995
R41 · FY2020 · CA · contact PI
Immune Regulation of Lung Squamous Metastasis$381,053
R01 · FY2019 · CA · contact PI
Immune Regulation of Lung Squamous Metastasis$426,393
R01 · FY2018 · CA · contact PI
Immune Regulation of Lung Squamous Metastasis$400,580
R01 · FY2017 · CA · contact PI